Latest period
86.60M
YoY change
+30.9%
5Y CAGR
+20.4%
Peak year (2025)
39.48M
Latest annual
39.48M
Shares Outstanding history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: 39.48M
Shares Outstanding growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: +30.9%
Shares Outstanding history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | 39.48M | +30.9% | +9.32M | ||
| 2024 | 30.16M | +0.2% | +65,000 | ||
| 2023 | 30.10M | +1.6% | +470,000 | ||
| 2022 | 29.63M | +68.8% | +12.08M | ||
| 2021 | 17.55M | +12.6% | +1.96M | ||
| 2020 | 15.59M | +69.0% | +6.37M | ||
| 2019 | 9.23M | +46.2% | +2.92M | ||
| 2018 | 6.31M | +101.3% | +3.18M | ||
| 2017 | 3.14M | +3.9% | +117,000 | ||
| 2016 | 3.02M | +4.1% | +119,000 | ||
| 2015 | 2.90M | +16.7% | +415,000 | ||
| 2014 | 2.48M | -89.8% | -21.85M | ||
| 2013 | 24.33M | +672.7% | +21.18M | ||
| 2012 | 3.15M | — | — |
- 202539.48M+30.9%
- 202430.16M+0.2%
- 202330.10M+1.6%
- 202229.63M+68.8%
- 202117.55M+12.6%
- 202015.59M+69.0%
- 20199.23M+46.2%
- 20186.31M+101.3%
- 20173.14M+3.9%
- 20163.02M+4.1%
- 20152.90M+16.7%
- 20142.48M-89.8%
- 201324.33M+672.7%
- 20123.15M—
Shares Outstanding values are taken from Relmada Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Shares Outstanding at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's latest reported diluted shares outstanding is 86.60M. Diluted weighted-average shares outstanding is the share count used to compute per-share metrics like EPS. Buybacks lower it; new issuance, stock-based compensation, and convertible securities raise it. Multiply by the stock price for market capitalization.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Relmada Therapeutics (RLMD) diluted shares outstanding is 39.48M – surged 30.9% year-over-year.
Through 2020–2025 (5 years), Relmada Therapeutics diluted shares outstanding delivered a +20.4% annualised rate; sustaining 11 straight years of year-over-year growth.
The record annual diluted shares outstanding stands at 39.48M, reached in 2025; the historical low of 2.48M was recorded in 2014.
Relmada Therapeutics Shares Outstanding by Year
Relmada Therapeutics Shares Outstanding 2025: 39.48M
In 2025, Relmada Therapeutics reported diluted shares outstanding of 39.48M, surged 30.9% from 2024. This figure represents the highest annual value in the available history.
Relmada Therapeutics Shares Outstanding 2024: 30.16M
Relmada Therapeutics diluted shares outstanding in 2024 was 30.16M, edged up 0.2% from 2023.
Relmada Therapeutics Shares Outstanding 2023: 30.10M
2023's diluted shares outstanding for Relmada Therapeutics came in at 30.10M, edged up 1.6% from 2022.
Relmada Therapeutics Shares Outstanding 2022: 29.63M
Relmada Therapeutics posted diluted shares outstanding of 29.63M in 2022, surged 68.8% from 2021.
Relmada Therapeutics Shares Outstanding 2021: 17.55M
Relmada Therapeutics diluted shares outstanding in 2021 was 17.55M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Shares Outstanding
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest diluted shares outstanding
| 4.45B | |
| 2.51B | |
| 2.43B | |
| 1.77B | |
| 1.56B | |
| 910.00M | |
| 898.00M | |
| 542.00M |
- 4.45B
- 2.51B
- 1.77B
- 1.56B
- 910.00M
- 898.00M
- 542.00M
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation